J. Goldman & Co’s Syndax Pharmaceuticals SNDX Stock Holding History

J. Goldman & Co’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-81,100	Closed	-$1.07M	–	614
2024 Q4	$1.07M	Buy	+81,100	New	+$1.39M	0.03%	323

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's SNDX Position: Q2 2018 in Review

J. Goldman & Co sold out of Syndax Pharmaceuticals (SNDX) in Q2 2018, closing a stake of 39,538 shares — an estimated $563K sold.

J. Goldman & Co first reported a position in SNDX in Q2 2017 and held it in 4 quarters. The position peaked at $2.06M in Q2 2017. 84 funds tracked by Wall St. Rank hold SNDX as of Q2 2018.

J. Goldman & Co reported no remaining Syndax Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
J. Goldman & Co sold 39,538 Syndax Pharmaceuticals shares in Q2 2018, an estimated $563K.
J. Goldman & Co first reported a position in Syndax Pharmaceuticals in Q2 2017 and held it in 4 quarters.
J. Goldman & Co's Syndax Pharmaceuticals position peaked at $2.06M in Q2 2017.
84 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2018.

Based on J. Goldman & Co's 13F filing for Q2 2018, filed 14 Aug 2018.